Journal
FRONTIERS IN IMMUNOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2018.03176
Keywords
human dendritic cells; DC; monocyte-derived dendritic cells; mo-DC; cancer vaccines; cancer combination therapies
Categories
Funding
- Sao Paulo Research Foundation-FAPESP [2014/25988-1, 2014/26437-9, 2105/03314-1, 2016/01137-8]
- Coordination for the Improvement of Higher Education Personnel-CAPES
- National Council for Scientific and Technological Development-CNPq [308053/2017-6]
Ask authors/readers for more resources
Dendritic cells (DC) are professional antigen presenting cells, uniquely able to induce naive T cell activation and effector differentiation. They are, likewise, involved in the induction and maintenance of immune tolerance in homeostatic conditions. Their phenotypic and functional heterogeneity points to their great plasticity and ability to modulate, according to their microenvironment, the acquired immune response and, at the same time, makes their precise classification complex and frequently subject to reviews and improvement. This review will present general aspects of the DC physiology and classification and will address their potential and actual uses in the management of human disease, more specifically cancer, as therapeutic and monitoring tools. New combination treatments with the participation of DC will be also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available